Immunocytochemistry/ Immunofluorescence: Lgr5/GPR49 Antibody [NBP1-28904] - Hek293 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were ...read more
Immunohistochemistry-Paraffin: Lgr5/GPR49 Antibody [NBP1-28904] - Wnt-related genes selectively expressed in human adrenal ZG. IHC localization of Lgr5/GPR49 & Wnt signaling proteins in ZG: canonical beta-catenin ...read more
Flow (Intracellular): Lgr5/GPR49 Antibody [NBP1-28904] - An intracellular stain was performed on HepG2 cells with Lgr5/GPR49 Antibody NBP1-28904AF647 (blue) and a matched isotype control (orange). Cells were fixed with ...read more
Immunohistochemistry: Lgr5/GPR49 Antibody [NBP1-28904] - Analysis of human small intestine.
Immunohistochemistry-Frozen: Lgr5/GPR49 Antibody [NBP1-28904] - Staining on pig small intestine. Image from verified customer review.
GPR49/LGR5 (G protein-coupled receptor 49 / leucine-rich repeat-containing G protein-coupled receptor 5), also called FEX, GPR67, GRP49, HG38 or MGC117008), is structurally related to members of glycoprotein hormone receptor family including FSH-R, TSH-R and LH-R. LGRs (leucine-rich repeat-containing G-protein coupled receptor) are divided into three major subgroups: glycoprotein hormone receptors; the subgroup of GPR48, GPR49, and LGR6; and receptors of relaxin family ligands (LGR7 and LGR8), of which GPR49 is emerging as a significant player in stem cells biology as it is highly expressed on stem cells in small intestine, colon and hair follicle. Deficiency of GPR49 in mice has been shown to cause neonatal lethality characterized by ankyloglossia, gastrointestinal distension and induction of premature differentiation of Paneth cells. LGR5 is a downstream target gene of Wnt signaling pathway (critical for morphogenesis and tumorigenesis) and it has also been reported as a receptor for R-spondins which are potent mediators of Wnt/beta-catenin as well as Wnt/PCP signaling. Accordingly, when compared to normal tissues, LGR5 is found upregulated in certain cancers e.g liver cancer with beta-catenin mutations, basal cell carcinoma, colon and ovarian carcinomas.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for Lgr5/GPR49 Antibody (NBP1-28904). (Showing 1 - 3 of 3 FAQs).
This morning I have a customer who has purchased NBP1-28904 and would like to test it in flow cytometry. She is new to flow and is wondering if you might have a recommended protocol. Also, I see that the immunogen is within aa 650-700 which appears to span both helical and cytoplasmic domains. Do you know if the exact immunogen is fully within one domain or the other? Is permeabilization required? Any information you have is much appreciated.
Unfortunately I cannot disclose anything more about the immunogen sequence; however, our lab does recommend permeabilization for using this antibody. This is our general flow cytometry protocol. Note that if she tests this antibody in flow, she would be eligible for our Innovators Reward Program.
Is it possible to confirm that the actual immunogen is taken from within the actual cytoplasmic domain (aa 660-682)?
Yes, I can confirm that the immunogen falls within the cytoplasmic domain of this protein.
Please inform us this item NBP1-28904 is stain cytoplasmic or stain Nuclus?
NBP1-28904 detects Lgr5/GPR49 protein which localize to Cell membrane and the Golgi apparatus. Therefore, this antibody should generate a staining pattern with more signal in membranes and in cytoplasm as patches around the nucleus of the cells. More information on this protein may be found at Uniprot site
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.